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Abstract  
Hepatitis B virus, the most infectious health burden worldwide. Significant HBV in community. HBV infection 
is prevailing all around rapidly. Factors to proceed HBV. Poor cognition regarding hepatitis B, undeveloped 
education about health care, severe stigma in society , and also the unsatisfactory medical services. Barriers : 
Lack of proper diagnosis and treat due to the lack of awareness about it ,lack of health care providence  
Conclusion: Improvement in education about health services and treatment can make this all better and this may 
be achievable through well organized and targeted community based screening and educational interventions. 
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Introduction 
HBV infection is prevailing around rapidly [1] [2]. Chronic HBV can be detected by the presence of an antigen 
(HBeAg) for six months in the blood or serum [3] [4]. In most people it is not very severe. In fact it does not 
create significant health problem but in some cases it proceeds to the liver fibrosis, cirrhosis and hepatocellular 
carcinoma (HCC) [5]. 
HBV is associated with the liver disease by the HBV DNA level in the blood. If the treatment like any 
antiviral treatment is not done, the cirrhosis may range from 8% to 20% [6] [7]. In cirrhosis, the decompensated 
liver disease have to face if remain untreated. In this way only 15% people can survive within five years in 
cirrhosis. Chronic hepatitis B based on the presence or absence of antigen is divided into two (HBeAg) positive 
or HBeAg negative. HBeAg is highly associated with the increased viral replication and so the increased 
effectivity. The main achievement is to prevent from cirrhosis, HCC and liver failure .On many scales surrogate 
markers are used to monitor the treatment response and the proceeding of this disease, and it includes in decrease 
in the inflammation  
With no improvement on liver biopsies in fibrosis, making normal the serum alanine aminotransferase level, 
lacking serum HBV, DNA to un-detachable levels [8]. It may include the conversion from HBeAg to HBe 
antibody and the loss from HBsAg to HBs antibody. 
When the adults experience the acute hepatitis B at the time of initial infection they face many conditions 
like anorexia, nausea, vomiting, and mostly the jaundice. It is approximately 30 to 50 % in adults and 30 to 90% 
in children and infants and less from all above 2 to 6% among adolescents the chronic infection will may vary 
[9]. 
There is no confirmation of the liver disease in the persons with the chronic HBV infection and its high 
level of replication in the liver cells ( hepatocytes) does not happens in spite the remaining  have the 
hepatitis ,(mild , moderate or severe) which lead the HCC and cirrhosis .There is 15% to 25% lifetime risk of 
death from chronic liver disease . Chronic infection ratio fluctuate according to the age [10]. 
 
Methodology 
To know about the hepatitis in the community, many patients with HBV were collected. And the same people 
living in that community. And the health care providers.  And also they reached to the people wished to be 
interviewed. For this a hospital, health services communities, offices of controlling the diseases and other non- 
governmental organizations (NGO) were contacted. The participants showed the complete consent that they 
desired to be interviewed and met the criteria needed for interview. CDC employee were leading the prevention 
programmes. This interview got the appreciation due to its much extensive literature broadcasting. The questions 
asked were about the basic introductions by name, age, work, ailment, and cure, the situation present and the 
resistance creating for the disease overcome. A single hepatitis patient with a resident of community was 
interviewed by a single health service doctor before the actual interview. Two mainly experienced interviewers 
run the whole interview. One female was recording the main points and the interview was headed by a male 
researcher. As per individual the interviews were taken separately to avoid any confusions. The data taken by the 
interviews was for the purpose of research. The interviews were 20-40 minutes longer. When maximum data for 
research was collected the interview stopped. A framework theme created for the research by team. The recorded 
texts were translated into English by the person who could use the proficient English .The research work was 
appreciated by the medical universities. 
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Significant Environment Hepatitis B Virus 
The prevention services, treatment, care is needed to overcome the early identification of HBV. Further 
knowledge is as added after the research about access to vaccination, and the awareness of HBV among people 
and also the prevention from the delivery of this virus. Hepatitis B screening programmes were started in USA to 
overcome this virus. There are many other un- identified HBV carriers exist which may remain in higher ratio.  
The testing ratio of HBV is less in Asian, and in audition, the vaccination also. The chemotherapy is also 
induced for its treatment. Another thing all the patient who had hepatitis in past can prevent from its reactivation 
by an antiviral prophylaxis which is recommended. This will lower the risk of HBV reactivation for the people 
which are undergoing chemotherapy.  This can prevail in different ages.  Educational awareness is the main need 
of this issue.   
 
Factors to proceed HBV 
Certain factors are there disseminator of this HBV, which may spread through the body fluids from a suffering 
person or through the blood contact or semen from such infected person. It may also be due to the factors below: 
 Intimation with different such partners or with the infected person of HBV  
 Usage of polluted syringes or needles in medicinal uses  
 Homosexuality  
 Company or permanent living with someone with the chronic HBV suffered  
 Sometimes babies may born from the infected women  
 Sometimes people get it who mostly keep in touch with the blood of human or exposed to the blood 
mostly  
 Many areas which are highly polluted like Asia,  Eastern Europe and Africa etc. travel in such areas is 
also another major factor. 
 
Statistics apply infected ratio from HBV in Pakistan 
About seven to nine million people are the carrier of this dangerous virus in accordance with the carrier rate of 
about three to five percent in Pakistan. This information reviews about its prevailing ratio and its factors, 
genotype of HBV and the available literature in Pakistan. Almost 106 different studies are included in this study. 
Proper mentioned graphs are designed for all the population group.  The different ratios observed about this 
HBV are in patient with cirrhosis 28.8% ,patient with hepatitis 15.8%  ,patient with liver disease 
27.54% ,prisoners 5.75% ,pregnant women 5.8% health care persons 3.2% , ophthalmic patients 3.8% multiple 
transfused patients 6.2% and the user of the drugs like injectable are 14.9% [12][13]. 
The major genotype exist and rapidly spreading in Pakistan is genotype D 63%. On urgent basis, awareness 
programme should be started in this prevailing HBV population [14].  
 
Major barriers to the prevention and control of HBV 
Deficiency of diagnosis resources and treatment for the suffering people, and proper lack of knowledge of HBV 
and the major factor is social stigma. The economic crisis of the country leave a bad impact on the public health 
spending, where investments deficiencies are preventing the proper treatment all around the country . Most 
people argue that they are always lack of knowledge about HBV from the medical and health centres. Social 
stigma surrounds the hepatitis B, and also the social discrimination. Not enough education in the community 
about Hepatitis B and C. Our education about health and hepatitis B in the community still not meet the need of 
residents. The community health care services have provided with the high blood pressure, heart diseases, and 
diabetes on daily basis. But the health education about HBV prevention and control are still rare.  
 
Community-based prevention from the liver cancers 
As one million people were dying every year, in 2010, the world Health Assembly invented or introduced an 
approach, to HBV control of all forms and prevention.  This infection is strongly endemic in countries like Asia. 
And which is going to be a long lasting chronic Hepatitis B which also has complications like life- threatening 
cirrhosis, hepatocellular cancer in most cases [11]. 
In Australian men, this chronic Hepatitis B and liver cancer ratio is over two lakh. There in Australia it is 
detected when it has gone to severe complications level, where there is lack of screening as well for this chronic 
HBV. In the many comparison were organized. There among the immigrants of south wales- Australia’s state 
suffering HCCs with the individuals which were born in Australia but from china migrants Korea has the 
greatest ratio of HCCs. There also screening for the chronic HBV is required to improve the treatment, diagnosis 
education and cure. There are decided some interventions which are multi-pronged to lessen the HBV related 
liver cancer in the people who are of migrant community. After these all efforts a programme, B positive 
programme was established which included the education, benefits and primary care from HBV for migrant 
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people which was registered. 
 
Conclusion 
There was a clear gap about the awareness of urgent need and demand for the proper health care centres to 
prevent from the HBV. Social discrimination has limited to get rid of HBV or to prevent from HBV. Lack of 
qualified staff and very less knowledge publically are other major factors. So the standard treatment, proper 
diagnosis, and other health services including screening should be managed and enough available in the 
community. Reduce stigma, provide a solid supported policy and some campaign about it from the GOVT.  
Due to people are dying on the ratio like death on road in road traffic injuries ,Diabetes, HIV and AIDS, 
And even the deaths from other killers like (Malaria, tuberculosis, and HIV) are reduced but the HIV risk is 
rising up. But this increasing death ratio can be overcome. 95% immunity is gained by only 3 doses of vaccine of 
HBV. As it is known it is not properly cured but its treatment can reduce its rising level. It is estimated by WHO 
that this prevention from higher rising risk will may 7.1 million people by 2030.The prevention and improving 
cured are prevailing more to improve this ambitious goal for any reduction of risk of disease .Firstly, understand 
the true ratio of that disease in that society.  
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